Posted by Michael Wonder on 31 Oct 2022
FDA accepts for priority review Ascendis Pharma’s NDA for TransCon PTH in adult patients with hypoparathyroidism
31 October 2022 - PDUFA target action date is 30 April 2023.
Ascendis Pharma today announced that the US FDA has accepted for priority review its new drug application for TransCon PTH (palopegteriparatide) in adult patients with hypoparathyroidism.
